Production (Stage)
ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 90.00K | 90.20K | 86.20K | 84.60K | 71.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 90.00K | 90.20K | 86.20K | 84.60K | 71.30K |
| Cost of Revenue | 913.00K | 38.10K | 39.50K | 41.50K | 1.63M |
| Gross Profit | -823.00K | 52.10K | 46.80K | 43.00K | -1.56M |
| SG&A Expenses | 1.27M | 1.59M | 2.37M | 1.59M | 2.88M |
| Depreciation & Amortization | 565.80K | 528.60K | 531.30K | 534.80K | 599.00K |
| Other Operating Expenses | 137.90K | 26.40K | 129.40K | 62.30K | 61.70K |
| Total Operating Expenses | 3.16M | 2.77M | 3.49M | 2.45M | 5.52M |
| Operating Income | -3.07M | -2.68M | -3.40M | -2.36M | -5.45M |
| Income Before Tax | -16.98M | -2.89M | -3.53M | -2.49M | -22.25M |
| Income Tax Expenses | -1.46M | -12.50K | -12.40K | -12.60K | -4.26M |
| Earnings from Continuing Operations | -15.53M | -2.87M | -3.52M | -2.48M | -18.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.53M | -2.87M | -3.52M | -2.48M | -18.00M |
| EBIT | -3.07M | -2.68M | -3.40M | -2.36M | -5.45M |
| EBITDA | -2.83M | -2.15M | -2.87M | -1.83M | -5.14M |
| EPS Basic | -0.21 | -0.04 | -0.05 | -0.03 | -0.26 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.02 | -0.06 |
| EPS Diluted | -0.21 | -0.04 | -0.05 | -0.04 | -0.26 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.02 | -0.06 |
| Average Basic Shares Outstanding | 74.37M | 72.18M | 70.85M | 70.85M | 70.04M |
| Average Diluted Shares Outstanding | 74.37M | 72.18M | 70.85M | 70.85M | 70.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |